Constantine Tam

78PUBLICATIONS

317CO-AUTHORS

Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Language documentation and descriptionPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (78)

Sort by Publication Date:

|Jul 13, 2026

Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study.

|Jul 07, 2026

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

|Jun 11, 2026

Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up.

|Jan 31, 2026

Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Mazyar Shadman, Asher Chanan-Khan, David Campbell

|Jan 08, 2026

First-line treatment for CLL in the era of targeted therapy.

Matthew S Davids, Stephan Stilgenbauer, Constantine S Tam

|Nov 18, 2025

Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.

Richard T Maziarz, Michael R Bishop, Constantine S Tam

Pageof 13

Frequent Collaborators

17 joint publications

John Francis Seymour

13 joint publications

Stephen S Opat

Judith Trotman

Andrew W Roberts

Mazyar Shadman

Jennifer R Brown

Thomas E Lew

Paolo Ghia

Sasanka M Handunnetti

6 joint publications

Steven P Treon

Frequent Collaborators

17 joint publications

John Francis Seymour

13 joint publications

Stephen S Opat

9 joint publications

Judith Trotman

8 joint publications

Andrew W Roberts